⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15864669 | 0.85 | — | — | |
| SCHEMBL12796336 | 0.67 | — | — | |
| SCHEMBL23566926 | 0.65 | — | — | |
| SCHEMBL1088263 | 0.61 | — | — | |
| SCHEMBL1087663 | 0.61 | — | — | |
| SCHEMBL1087661 | 0.61 | — | — | |
| SCHEMBL1517881 | 0.61 | — | — | |
| SCHEMBL12112650 | 0.60 | — | — | |
| SCHEMBL9243173 | 0.60 | — | — | |
| SCHEMBL5353505 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021053589-A1 | COMPOUNDS FOR THE INDUCTION OF ANTIGEN-SPECIFIC IMMUNE TOLERANCE | ANOKION SA (CH) | 2021-03-25 | — | — | WO | disclosed |
| EP-3072897-B1 | SPIROKETAL DERIVATIVES AND USE THEREOF AS DIABETIC MEDICINE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2019-06-26 | — | — | EP | disclosed |
| EP-2991980-B1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-01-02 | — | — | EP | disclosed |
| US-20180186814-A1 | TRICYCLIC COMPOUND HAVING SULFINYL OR SULFONYL | SHIONOGI & CO., LTD. (JP) | 2018-07-05 | — | — | US | disclosed |
| EP-3318567-A1 | TRICYCLIC COMPOUND HAVING SULFINYL OR SULFONYL | Shionogi & Co., Ltd (JP) | 2018-05-09 | — | — | EP | disclosed |
| US-9790212-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| EP-3019494-B1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD (GB) | 2017-06-21 | — | — | EP | disclosed |
| US-20170029412-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-02-02 | — | — | US | disclosed |
| US-9556157-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-01-31 | — | — | US | disclosed |
| US-9505745-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-11-29 | — | — | US | disclosed |
| WO-2012048411-A1 | PLK-4 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2012-04-19 | — | — | WO | disclosed |
| US-20100234609-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-09-16 | — | — | US | disclosed |
| US-7767651-B2 | Spiroketal derivatives and use thereof as diabetic medicine | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20100093744-A1 | THIOGLUCOSE SPIROKETAL DERIVATIVE AND USE THEREOF AS THERAPEUTIC AGENT FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2072522-A1 | THIOGLUCOSE SPIROKETAL DERIVATIVE AND USE THEREOF AS THERAPEUTIC AGENT FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-06-24 | — | — | EP | disclosed |
| EP-2048152-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS DRUG FOR TREATING DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20090030006-A1 | SPIROKETAL DERIVATIVES AND USE THEREOF AS DIABETIC MEDICINE | CHUGAI SEIYAYAKU KABUSHIKI KAISHA | 2009-01-29 | — | — | US | disclosed |
| EP-1852439-A1 | SPIROKETAL DERIVATIVE AND USE THEREOF AS DIABETIC MEDICINE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-11-07 | — | — | EP | disclosed |
| US-7217723-B2 | Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. | EISAI CO., LTD. (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20050227959-A1 | Heterocyclic compound having oxime group | EISAI CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |